Lonza will expand commercial manufacturing capacity at its Houston cell and gene therapy site to support Genetix Biotherapeutics’ ZYNTEGLO, the only FDA‑approved gene therapy for transfusion‑dependent beta‑thalassemia. The renewed agreement continues a long‑standing partnership and includes provisions for scaling capacity to meet growing patient demand and future Genetix programs. The expansion underscores consolidating trends in bespoke gene‑therapy manufacturing and the importance of dedicated facilities that can scale from clinical to commercial supply for curative modalities. Lonza framed the move as part of a strategic, quality‑focused manufacturing backbone to support wider access to approved and pipeline cell and gene therapies.